SAGE Therapeutics Inc (NASDAQ:SAGE) Insider Trading Activity – Director Sold 49,461 shares of Stock

ME Staff
-
0

Insider Trading Activity For SAGE Therapeutics Inc (NASDAQ:SAGE)

Steven M Paul , Director of SAGE Therapeutics Inc (NASDAQ:SAGE) reportedly Sold 49,461 shares of the company’s stock at an average price of 161.02 for a total transaction amount of $7,964,210.22 SEC Form

Insider Trading History For SAGE Therapeutics Inc (NASDAQ:SAGE)

  • On 7/23/2014 Stephen Kanes, Insider, bought 3,000 with an average share price of $18.00 per share and the total transaction amounting to $54,000.00.
  • On 7/23/2014 James M Frates, Director, bought 5,000 with an average share price of $18.00 per share and the total transaction amounting to $90,000.00.
  • On 1/26/2015 Stephen Kanes, Insider, sold 6,000 with an average share price of $37.29 per share and the total transaction amounting to $223,740.00.
  • On 2/25/2015 Stephen Kanes, Insider, sold 6,000 with an average share price of $42.05 per share and the total transaction amounting to $252,300.00.
  • On 6/1/2015 Steven M Paul, Director, sold 20,000 with an average share price of $72.34 per share and the total transaction amounting to $1,446,800.00.
  • On 6/1/2015 Albert Robichaud, Insider, sold 16,000 with an average share price of $72.80 per share and the total transaction amounting to $1,164,800.00.
  • On 6/8/2015 Thomas Anderson, Insider, sold 5,500 with an average share price of $79.65 per share and the total transaction amounting to $438,075.00.

    • Analyst Ratings History For SAGE Therapeutics Inc (NASDAQ:SAGE)

    • On 8/4/2017 HC Wainwright Boost Price Target of rating Neutral with a price target of $86.00
    • On 10/6/2017 Goldman Sachs Group Reiterated Rating Buy to Buy with a price target of $87.00
    • On 11/10/2017 Chardan Capital Upgraded rating Neutral to Buy with a price target of $60.00 to $140.00
    • On 11/16/2017 Bank of America Lower Price Target of rating Buy with a price target of $103.00 to $101.00
    • On 12/7/2017 BMO Capital Markets Reiterated Rating Outperform with a price target of $203.00
    • On 12/7/2017 Raymond James Reiterated Rating Buy with a price target of $206.00
    • On 2/23/2018 Needham & Company LLC Reiterated Rating Buy with a price target of $193.00

    Recent Trading Activity for SAGE Therapeutics Inc (NASDAQ:SAGE)
    Shares of SAGE Therapeutics Inc closed the previous trading session at 152.95 −7.98 4.96% with 149.52 shares trading hands.